Biotech in China 2021, at the beginning of the 14th five-year period ("145")

2021年中国生物技术发展现状,正值第十四个五年期(“145”)伊始

阅读:1

Abstract

As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird's eye view on how the bio-digital revolution impacts China's biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure in science, information technology, and education, China's biomedical and MedTech industries prosper. Plant and animal breeding programs transform agriculture and food supply as much as the Internet of things, and synthetic biology offers new opportunities for the manufacturing of specialty chemicals within the Chinese version of a "bioeconomy." It is already becoming apparent that the new five-year period "145" (2021-2025) will further emphasize emission control, bioenvironmental protection, and more supply of biomass-derived energy. This review identifies key drivers in China's government, industry, and academia behind these developments and details many access points for deeper studies. KEY POINTS: Biotechnology in China Biomedical technology New five-year period.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。